Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults - Wikidata - wikimedia - TriplyDB

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

http://www.wikidata.org/entity/Q36181531

about

Prospects for dengue vaccines for travelers Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control The dengue vaccine pipeline: Implications for the future of dengue control Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment Recent advances in understanding dengue Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine Patterns of cellular immunity associated with experimental infection with rDEN2Δ30 (Tonga/74) supports its suitability as a human DENV challenge strain Historical Perspectives on Flavivirus Research In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers.Immune correlates for dengue vaccine development Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits.Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge.A novel indirect ELISA for diagnosis of dengue fever.Prevention and Control Strategies to Counter Dengue Virus Infection.Immune correlates of protection for dengue: State of the art and research agenda.Working towards dengue as a vaccine-preventable disease: challenges and opportunities.A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.A recombinant live attenuated tetravalent vaccine for the prevention of dengue.Vaccines licensed and in clinical trials for the prevention of dengue.Development of Peptide Vaccines in Dengue.Therapeutic Effects of Monoclonal Antibody against Dengue Virus NS1 in a STAT1 Knockout Mouse Model of Dengue Infection.The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans.A Promising, Single-Dose, Live Attenuated Tetravalent Dengue Vaccine Candidate.Dengue infection.Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4.Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies.Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513.Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice

P2860

Q26314423-128717E4-89A5-4068-B5A3-31F0C83280A5 Q26314452-802D4AC3-2FF3-41F2-8A6D-2A84B5B13F5D Q26314683-1366287B-E755-45CF-BF2A-2F931C4B0C40 Q26746185-0FC4894C-42A9-4778-A7EA-0F2FD983C2A9 Q26766156-75E7106E-AB4B-4A20-BC8B-B2C549581F82 Q26782367-52FC3695-401A-4AFE-B8F1-E4C8A2F7E987 Q28729784-CD8234AA-6C77-4AFE-9580-54145B3B3F24 Q29994534-19BD3E43-AF1F-4E0D-85F2-710C370AF4FE Q30250977-8BCAB1F3-A51F-4D2D-8557-BD11F7FB24B0 Q33425879-B7F09A55-66A7-41D6-A0B0-222B0A2A22CE Q33867337-21D44778-71C1-46D1-889B-41D5106F2365 Q33924674-F69D62DA-0513-4D71-B5AF-CCAD20B266A9 Q34522384-A2FEC0BF-4662-424C-B405-1A11EBD65B5E Q36206719-A5D108F1-0B9C-42AD-B0CA-A570B3AE7F21 Q37115807-0435E08E-2BAD-476F-B64C-28FC64EA147D Q37336555-88EBD6EC-D143-4470-8F63-174550AE15EB Q37425337-C7AC8DD1-60C0-4D36-8F54-F8D321141D40 Q38368332-EBEAE05D-CA2E-4930-A243-3CFEFC0174B5 Q38652971-599169BA-67E6-4329-A494-0096D1B28408 Q38657783-54E8D77A-F2A2-476D-92C9-5B77926BF575 Q38658737-622F2F39-B7FF-476F-945B-AD1F72A38402 Q38738484-E012D538-C6DB-423C-9092-2065E0AB3AA5 Q39172722-6F27A09B-6FEA-4BCB-AF41-C5DBAD7AA7ED Q40038715-8303111A-9A7E-475D-9478-004DE065334C Q40039016-1A355607-345A-4C97-A8F5-5572430ADD2A Q40109446-BD220B2E-B0AD-4D25-BE31-7CE91A2B7020 Q40116968-7279216E-BF85-4224-A07B-9A9E68B93D85 Q41924182-393156B3-A992-428E-B44F-8244A88BA15C Q42977175-5FECA020-B7B8-42DC-9F2B-BD65FF0A5E51 Q42996339-F29215B5-656B-4E9A-B0DC-EAC3C91560FE Q45323668-A395BE8C-D3BF-49FC-B984-A2FC5E5F3BC9 Q47562022-391FCAE9-85D4-414B-84B9-16875858A7CF Q52662743-181BCF70-8C11-424B-9CE9-051478B56DDE Q55363151-E507382A-FAB5-45FC-8278-13B9CD1BBB0D Q56888687-4FA40461-5899-4246-AF9D-5F12EBBF0469

P2860

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

http://www.wikidata.org/entity/Q36181531

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Robust and Balanced Immune Res ...... althy, Flavivirus-Naive Adults

@ast

Robust and Balanced Immune Res ...... althy, Flavivirus-Naive Adults

@en

type

label

Robust and Balanced Immune Res ...... althy, Flavivirus-Naive Adults

@ast

Robust and Balanced Immune Res ...... althy, Flavivirus-Naive Adults

@en

prefLabel

Robust and Balanced Immune Res ...... althy, Flavivirus-Naive Adults

@ast

Robust and Balanced Immune Res ...... althy, Flavivirus-Naive Adults

@en

P1433

Q36181531-7F04E084-69D4-4D00-AA84-8040A363F37F

P1476

Q36181531-43600DB9-71FE-4B26-8675-06925F3C0258

P2093

Q36181531-204ED243-36A9-49C9-A081-4BD47FC06A8C

Q36181531-38BDB5E9-EE9A-4DF0-BE8E-63A6D15E93E9

Q36181531-44297BFD-0388-42AB-A211-24AD3687DB7A

Q36181531-44F22DE7-A752-4540-9FC0-EBAAB6E3765A

Q36181531-612B9B96-3561-4B07-9D52-106506B4DEED

Q36181531-69BF38E1-3BA9-41DE-B6A2-85BBF59BBCC8

Q36181531-6B6EFA53-A430-4D30-953F-924313FADFC3

Q36181531-6EBB32B4-D400-4ACC-A351-29F88847D334

Q36181531-919FAEB4-5BFB-4A59-86BE-540EAAE50AE8

Q36181531-A0BC0237-5868-4E42-A6B9-4034F7CDD950

P2860

Q36181531-0576F12A-64E7-4759-A360-110D5E9C0348

Q36181531-0E624C06-4AD0-445E-8654-EE1DEEBCC6C8

Q36181531-11A8476D-B92A-4C7A-9045-CA4DCECFF96D

Q36181531-2BDB17A7-0F42-4AFA-B718-D0DB17088D17

Q36181531-461BAC0A-CE00-407A-8AB9-069360497655

Q36181531-46983FFA-AD20-418C-B7AB-5F3892423F3F

Q36181531-49A263B8-4589-4782-8A02-E9D04735DDF3

Q36181531-4C59BDC3-6DEA-4958-B0EA-A5BDFD196F30

Q36181531-52109D0F-EEAA-4FC6-902C-02B2FEEDC587

Q36181531-5C09B982-FFA8-4E6C-BD34-58A40E8B3CD8

P304

Q36181531-6F99B77F-7725-4C7D-8FDF-081E2D05B611

P31

Q36181531-F760CD1B-AE43-4DEC-97C4-37498B564430

P356

Q36181531-9C1B0FDC-4B38-49C7-9FA6-982A081AF1CA

P407

Q36181531-36923140-7DB6-4135-AB3B-3DF592240C33

P433

Q36181531-D692B4DB-6086-4349-A38C-5972CEECB9EF

P478

Q36181531-25922B1F-29F1-4ECD-A4B0-321AF9838E0E

P50

Q36181531-46B96697-4FC9-4A66-8F4A-87D85A0EA0F7

Q36181531-EC8EFCF5-2ABF-4BAA-B0A0-268D6F0D5978

P577

Q36181531-45054D4F-0D2E-44A4-90CE-57C500C5BD3B

P5875

Q36181531-7B47B83D-40DC-425F-9758-5A47FEFE123F

P698

Q36181531-D56757F0-5ABD-43EE-BF03-D34995B11E97

P921

Q36181531-59780186-30EF-49AC-9B2E-31B65A50A55E

Q36181531-E6967126-117A-45DD-9FAD-D95A3D877A74

P932

Q36181531-3DB49DFC-9114-4EA0-8C40-87C0EB116406

P356

P1433

The Journal of Infectious Diseases

P1476

Robust and Balanced Immune Res ...... althy, Flavivirus-Naive Adults

@en

P2093

Adrienne P Jarvis

http://www.w3.org/2001/XMLSchema#string

Beth D Kirkpatrick

http://www.w3.org/2001/XMLSchema#string

Beulah P Sabundayo

http://www.w3.org/2001/XMLSchema#string

Caroline E Lyon

http://www.w3.org/2001/XMLSchema#string

Catherine J Larsson

http://www.w3.org/2001/XMLSchema#string

Catherine J Luke

http://www.w3.org/2001/XMLSchema#string

Cecilia M Tibery

http://www.w3.org/2001/XMLSchema#string

Dan Elwood

http://www.w3.org/2001/XMLSchema#string

Ellen A Fraser

http://www.w3.org/2001/XMLSchema#string

Janece M Lovchik

http://www.w3.org/2001/XMLSchema#string

P2860

The global distribution and burden of dengue

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity

Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult Volunteers

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards

Research on dengue during World War II

A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.

Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans.

P304

702-710

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIV082

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

212

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274086743

http://www.w3.org/2001/XMLSchema#string

P698

25801652

http://www.w3.org/2001/XMLSchema#string

P921

attenuated vaccine

P932

4612392

http://www.w3.org/2001/XMLSchema#string